Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(44.4%)
Phase 2
3(33.3%)
Phase 1
2(22.2%)
9Total
Phase 3(4)
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT07023965Enrolling By Invitation

Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

Role: lead

NCT04274049Phase 3Completed

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

Role: lead

NCT04275323Phase 3Completed

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)

Role: lead

NCT05984134Phase 2Completed

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

Role: lead

NCT05968118Phase 3Unknown

Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients

Role: lead

NCT05485818Phase 2Completed

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Role: lead

NCT04555824Phase 1Completed

A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

Role: lead

NCT04555850Phase 1Completed

A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers

Role: lead

NCT01663441Phase 3Completed

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Role: lead

NCT01548378Phase 2Completed

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Role: lead

All 10 trials loaded